masteron hair loss
Combined use of alendronate masteron hair loss (but not simultaneous reception) with estrogen drugs, are not accompanied by a change in their actions and the development of side effects.
It is not allowed simultaneous in time receiving alendronic acid preparations containing calcium, antacids or other medications for oral use due to a possible reduction in the absorption of alendronate. In this connection it is necessary to take a break for at least 30 minutes after administration of alendronic acid and prior to ingestion of other drugs.
Receiving oral prednisolone is not accompanied by a clinically significant changes in bioavailability of alendronate.
Non-steroidal anti-inflammatory agents enhance the side effects of alendronate on the gastrointestinal tract.
should pay special attention to any signs of adverse reactions in the area of the esophagus. The patient should be informed of the need to stop taking the drug and contact your doctor if you develop dysphagia, pain on swallowing, chest pain, new or worsening heartburn. It is necessary to inform the patient about the possible risk of damage to the esophageal mucosa non-compliance with instructions for use.
Due to the risk of irritation of the mucous membrane of the upper gastrointestinal tract, as well as the worsening of the underlying disease is recommended to be careful when masteron hair loss administering the drug to patients with diseases of the gastrointestinal tract, such as dysphagia, esophagitis, gastritis, duodenitis, gastric ulcer and 12 duodenal ulcer in the acute stage, as well as with the newly migrated (within the previous year), diseases of the gastrointestinal tract (stomach ulcer and 12 duodenal ulcer, active bleeding in the gastrointestinal tract, surgical intervention in the upper gastrointestinal tract but pyloroplasty).Patients should be informed that the missed doses should take 1 tablet in the morning after they remember about it.
In patients with hypocalcemia before initiating treatment of alendronic acid necessary to carry out corrective therapy disorders of mineral metabolism, including vitamin D deficiency and hypoparathyroidism.In the treatment of asymptomatic slight decrease the concentration of calcium and phosphate in the serum can be observed due to the positive effects of alendronate on bone mineral density. In addition, there are rare reports of symptomatic hypocalcemia, sometimes difficult flowing, which is often found in patients with hypoparathyroidism, vitamin D deficiency and impaired absorption of calcium.
When receiving masteron hair loss (especially when concomitant therapy with corticosteroids) is necessary to ensure adequate intake of calcium and vitamin D in the form of food or pharmaceuticals. Absorption of bisphosphonates is greatly reduced while eating.
It was reported about osteonecrosis of the jaw, generally associated with tooth extraction and / or local infection (including osteomyelitis) in cancer patients treated with intravenous bisphosphonates generally. Many of these patients were also receiving chemotherapy and corticosteroids.
There are also reports of osteonecrosis of the jaw in patients with osteoporosis receiving oral bisphosphonates.
Before prescribing treatment with bisphosphonates in patients with concomitant risk factors (eg cancer, chemotherapy, radiotherapy, taking corticosteroids, poor oral hygiene ) need to undergo dental examination with appropriate preventive dentistry.
Patients who are being treated with bisphosphonates, should as far as possible, avoid invasive dental procedures. In patients on bisphosphonate therapy, who developed osteonecrosis of the jaw, dental surgery may lead to a deterioration. If necessary, surgical interventions should be taken into account that the possibility of reducing the risk of osteonecrosis of the jaw data after the abolition of bisphosphonate absence.
Assignments and recommendations masteron hair loss of the treating physician should be based on an individual assessment of benefit / risk ratio for each patient.